Navigation Links
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
Date:2/17/2013

ZURICH, February 18, 2013 /PRNewswire/ --

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a  recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients ages 18 years and older.

Piromelatine 20/50mg treatment for 4 weeks resulted in statistically significant and clinically meaningful improvements relative to placebo in key  polysomnographic (PSG) parameters including Wake After Sleep Onset (WASO) (p=0.02 for both doses) and in particular WASO for the first 6 hours of sleep (WASO-6h) (p=0.0008 and p=0.04 for the 50 mg and 20 mg groups, respectively). Piromelatine 50 mg also improved Sleep Efficiency (SEF) (p=0.02), Total Sleep Time (TST) (p=0.02), Total Time Awake (TTA) (p=0.01) and time in NREM sleep (p=0.028) indicating beneficial effects on sleep maintenance. Subjective improvements relative to placebo in quality of sleep and total sleep time measured by the Pittsburg Sleep Quality Questionnaire (PSQI) were also observed, confirming the PSG findings. Piromelatine enhanced NREM sleep EEG delta power and significantly reduced beta power (p<0.05). The decrease in EEG beta activity, a marker of cortical arousal, is a physiological surrogate marker of the efficacy of Piromelatine in sleep maintenance. Piromelatine was generally safe and well tolerated, had no detrimental effects on next-day psychomotor performance (as assessed by the Digit Symbol Substitution Test (DSST)) for any dose group and no deleterious effects on sleep structure and architecture.

"Piromelatine demonstrates a good potential for the treatm
'/>"/>

SOURCE Neurim Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
(Date:8/29/2014)... , August 29, 2014 ... to participate in the inaugural Tweetchat taking place ... CPhI Worldwide , organised by UBM Live ... 2014. #CPhIChat is a first of its kind ... working across the supply chain, aimed to stimulate ...
(Date:8/28/2014)... NEW YORK, Aug. 28, 2014 Reportlinker.com ... available in its catalogue: North America ... 2020 http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Market Outlook to 2020 Summary GlobalData,s ... Devices Market Outlook to 2020", provides key market ...
Breaking Medicine Technology:Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... VIEW, Calif., Feb. 9, 2011 Concentric Medical, Inc. today ... ( T hrombectomy RE vascularization of large V ... in Portland, Oregon and at Capital Health in Trenton, New ... TREVO 2 and Capital Health was first to use the ...
... NEW YORK, Feb. 9, 2011 Reportlinker.com announces ... in its catalogue: Omega-3-acid ethyl ... http://www.reportlinker.com/p0366322/Omega-3-acid-ethyl-esters---Comprehensive-patent-search.html Eliminate unnecessary risk ... Pipeline Developer is a regularly updated, ...
Cached Medicine Technology:Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 2Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 2Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 4
(Date:8/29/2014)... For the fifth year in a row, ... observing September 26th as Mesothelioma Awareness Day, by attending ... , Members of the community who wish to ... will be providing t-shirts and signs to participating community ... have received attention from Al Roker and ...
(Date:8/29/2014)... Empty Nest Syndrome on Dr. Carol ... , Mothers and fathers, who dedicated the last ... laughing and sweating through parenting, launch their college ... Relief and parenting pride intermix with loss, depression ... Carol Francis as a Clinical Psychologist has helped ...
(Date:8/29/2014)... PreDiabetes Centers , the country’s leading prediabetes ... Web shoppers a 20% discount off orders of $100 or ... healthy living shop, beginning September 1. , Keeping your ... into the chilly fall season. , Autumn’s cooler, cozier weather ... usually ditch the healthy salads and opt for creamy soups, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 TayganPoint Consulting ... that for the second time, Inc. Magazine has named ... in America. , Based on solid revenue growth of ... No. 2341 overall on the list. TayganPoint’s repeat ... environment of the past few years, is a demonstration ...
(Date:8/29/2014)... 2014 Innovations Television, produced by DMG Productions, ... of Innovations, focusing on health and elderly care, slated to ... number of Americans over 65 will nearly double by 2030, ... in 2030, for a total of 72 million people. Though ... have at least one chronic condition and use healthcare services ...
Breaking Medicine News(10 mins):Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2
... new asthma inhaler revealed that it has problems. This investigation was ... the funding for Ventolin inhalers in favour of Salamol. ... Only 15 of them were able to stick to the study. ... or due to the taste. Asthma stability had deteriorated in 93% ...
... According to researchers, a gene determines people’s sensitivity to ... chronic pain could be prevented by blocking the expression ... inflammation. This could be a breakthrough in development of ... about a quarter of them had the genetic variant ...
... be dangerous as the tablet’s special coating controls the release ... serious side effects. ,David Wright, who led a ... take drugs in patch, liquid or inhaler form.”,Difficulty in swallowing ... Studies have revealed that tablets are being crushed and given ...
... interesting study conducted at National University of Singapore recently ... November 1, 2006 edition, to study the tangible benefits ... discovered that a regular consumption of meals which are ... degenerative processes of the brain which is often indelibly ...
... Butler, a pioneering plastic and reconstructive surgeon has been ... ethics committee of the Royal Free Hospital, London to ... ,However the Royal College of Surgeons has called for ... transplantation. ,The surgery promises to transform the lives ...
... a new drug for treatment of obesity, has been found to ... with diabetes type 2. The research was done on 1,047 overweight ... and North America. ,Some of them were given 5 or ... a placebo, for a 1 year period. Those on the drug ...
Cached Medicine News:Health News:Gene determines pain threshold... 2Health News:Spices in curries spruce up aging minds 2Health News:Green Signal given to Full-Face Transplants 2Health News:Green Signal given to Full-Face Transplants 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: